摘要
目的：探讨骨肉瘤组织蛋白酶Ｄ表达与肿瘤细胞增殖活性及骨肉瘤预后的关系。方法：运用免疫组织化学染色，检测８５例骨肉瘤细胞增核抗原（ＰＣＮＡ）及组织蛋白酶Ｄ（Ｃａｔｈ－Ｄ）的表达，计算其标记指数（Ｌａｂｅｌｉｎｇｉｎｄｅｘ即ＬＩ）。结果：Ｃａｔｈ－ＤＬＩ在６％～９８．５％之间，ＰＣＮＡＬＩ在９％～９８％之间，Ｃａｔｈ－ＤＬＩ与骨肉瘤患者的年龄、性别、肿瘤的大小及Ｄａｈｉｌｉｎ分型无关，而与ＷＨＯ１９９３年新分型，Ｐｒｉｃｅ分级及ＰＣＮＡＬＩ密切相关。生存率分析显示Ｃａｔｈ－ＤＬＩ＜６２．５％的骨肉瘤预后较好，＞６２．５％的骨肉瘤预后较差。结论：骨肉瘤Ｃａｔｈ－Ｄ表达与肿瘤细胞增殖活性及生存率密切相关。
Objective: To identify the relation of
cathepsin D (Cath D) expression to tumor cell proliferative activity and prognosis in
osteosarcoma. Methods: The expression of proliferating cell nuclear antigen (PCNA) and Cath
D in tumor cells were semiquantitatively analyzed with immunohistochemistry in a consecutive
prospective series of 85 osteosarcoma patients and the labeling index (LI) was calculated.
Results: In all the cases, the range of Cath D LI was 6%～98.5% and that of PCNA LI 9%～98%.
The Cath D LI was not correlated to the patient's sex, age, tumor size and Dahlin's type but
closely correlated with new WHO classification in 1993, Price's grade and PCNA LI.
Furthermore, the patients with a Cath D LI less than 62.5% showed a better survival than
those with a Cath D LI more than 62.5%. Conclusion: Cath D expression is closely related to
survival in osteosarcoma patients, which suggests that Cath D LI is an useful prognostic
indicator for osteosarcoma.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
1999年第2期109-112,共4页
Journal of Third Military Medical University
基金
全军"九五"青年基金
